Cover Image
Market Research Report
Product code 
858348

Market Spotlight: Fragile X Syndrome

Published: | Datamonitor Healthcare | 30 Pages | Delivery time: 1-2 business days

Price

Back to Top
Market Spotlight: Fragile X Syndrome
Published: June 10, 2021
Datamonitor Healthcare
Content info: 30 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

Fragile X syndrome (FXS) is a genetic disorder leading to various developmental problems ranging from learning disabilities to cognitive impairment. FXS is caused by mutation of the fragile X mental retardation 1 (FMR1) gene, which usually makes a protein known as fragile X mental retardation protein (FMRP). FMRP is required for normal brain development, and individuals with FXS do not make this protein. Individuals who have other fragile X-associated disorders (FXTAS) have mutations in their FMR1 gene, but they generally make some FMRP

Key Takeaways

Based on cohorts of children with special educational needs, the prevalence of fragile X syndrome (FXS) is estimated to be 1 in 4,000 in males, and 1 in 8,000 in females.

The majority of industry-sponsored drugs in active clinical development for FXS are in Phase II, with two drugs in Phase III. Therapies in active clinical development for FXS focus on targets such as cannabinoid-1/cannabinoid-2 receptor, phosphodiesterase 4, GABA-A receptor, insulin-like growth factor-1 receptor, GABA-B receptor, 11-beta-hydroxylase, 11 betahydroxysteroid dehydrogenase type 1, and potassium channels. The majority of these pipeline drugs are administered via the oral route.

The overall likelihood of approval of a Phase I neurodevelopmental disorders asset is 2.7%, and the average probability a drug advances from Phase III is 20%. Drugs, on average, take 12.4 years from Phase I to approval, compared to 10.0 years in the overall neurology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for FXS have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.

The US has a substantial lead in the number of FXS clinical trials globally. France and Spain lead the major European markets, while Israel has the top spot in Asia.

Clinical trial activity in the FXS space is dominated by completed trials. Seaside Therapeutics and Novartis have the highest number of completed clinical trials for FXS, with four trials each.

Seaside Therapeutics leads industry sponsors with the highest overall number of clinical trials for FXS, followed by Novartis.

Product Code: DMKC0191189

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

EPIDEMIOLOGY

  • Premutation

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • BPN14770 for FXS (November 2, 2020)
  • Zygel for FXS (October 15, 2020)
  • Zygel for FXS (June 30, 2020)
  • OV101 for FXS (May 7, 2020)

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Shionogi To Add CNS Critical Mass With Tetra Buyout

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for FXS in the US
  • Figure 2: Pipeline drugs for FXS, by company
  • Figure 3: Pipeline drugs for FXS, by drug type
  • Figure 4: Pipeline drugs for FXS, by classification
  • Figure 5: BPN14770 for FXS (November 2, 2020): Phase II - Adults
  • Figure 6: Zygel for FXS (October 15, 2020): Phase III - CONNECT-FX (US, AUS, NZ)
  • Figure 7: Zygel for FXS (June 30, 2020): Phase III - CONNECT-FX (US, AUS, NZ)
  • Figure 8: OV101 for FXS (May 7, 2020): Phase II - ROCKET
  • Figure 9: Probability of success in the neurodevelopmental disorders pipeline
  • Figure 10: Clinical trials in FXS
  • Figure 11: Top 10 drugs for clinical trials in FXS
  • Figure 12: Top 10 companies for clinical trials in FXS
  • Figure 13: Trial locations in FXS
  • Figure 14: FXS trials status
  • Figure 15: FXS trials sponsors, by phase

LIST OF TABLES

  • Table 1: Pipeline drugs for FXS in the US
  • Table 2: BPN14770 for FXS (November 2, 2020)
  • Table 3: Zygel for FXS (October 15, 2020)
  • Table 4: Zygel for FXS (June 30, 2020)
  • Table 5: OV101 for FXS (May 7, 2020)